Development of a Core Set of Patient- and Caregiver-Reported Signs and Symptoms to Facilitate Early Recognition of Acute Chimeric Antigen Receptor T-Cell Therapy Toxicities In this retrospective study ...

Stem Cell Therapeutics Corp. has announced the execution of a definitive license agreement with University Health Network ("UHN"), Toronto, Canada. The agreement, developed in collaboration with MaRS ...

Allogeneic SCT was introduced in the treatment of multiple myeloma (MM) 25 years ago, yet its role remains controversial. Although allogeneic SCT is possibly the only curative treatment and can induce ...

The short- and long-term physical and psychosocial sequelae of hematopoietic SCT (HSCT) have been extensively documented. HSCT has a range of well-recognized acute conditioning-related toxicities (for ...